Hypertension and renal disease are risk factors for increased morbidity and mortality in sickle cell disease
(SCD). Young SCD patients may develop microalbuminuria and hyposthenuria while hypertension increases
risk for stroke, a significant problem in pediatric SCD. Among 79 adolescent SCD patients at UAB, 31% have
hypertension as defined by NHLBI tables for age and height and 25% have microalbuminuria (>30mcg/mg).
Persistent untreated hypertension may contribute to the early prevalence of chronic kidney disease (CKD) in
SCD. The mortality rate in young adults with CKD on dialysis is high; 26% of young adults with SCD die within
one year of starting dialysis. Mean blood pressure (BP) should decrease while sleeping, but 90% of
adolescent SCD patients tested in our clinic have abnormal nocturnal dipping, a known pediatric risk
factor for adverse cardiovascular outcomes. Abnormal nocturnal dipping will be defined as <10% dip in BP
(mean daytime BP-mean nocturnal BP)/mean daytime BP x 100.) This high prevalence mandates a search for
evidence of benefit to normalization of nocturnal BP and the optimal BP treatment strategy in pediatric SCD.
This K23 proposal focuses on didactic and practical mentored training in the development of treatments for
SCD and in the conduct of SCD clinical trials. My long term goal is to initiate a phase III, multicenter trial to
define the role of antihypertensive therapy for SCD patients. My short term goals to be accomplished during
this K23 proposal focuses on developing expertise in trial design, conduct, and analysis. A mentorship team
with unique areas of expertise in clinical trials will mentor me in the conduct of 1) a prospective pediatric SCD
cohort study to evaluate changes in BP and blood/urine biomarkers of kidney injury over three years and 2) a
single site randomized feasibility trial of losartan in cohort patients identified with abnormal nocturnal dipping.
The three year prospective cohort will be used to define the incidence of hypertension (in-clinic and 24 hour)
and kidney injury among 200 SCD patients (6-19yrs). From this cohort, we expect to enroll 40 SCD patients
(11-19yrs) with abnormal circadian blood pressure in a six month feasibility trial to systematically evaluate the
acceptance and eligibility rates, adherence, dosing and safety for a losartan trial, and develop background data
on the effect of losartan in patients with abnormal nocturnal dipping.
Specific Aim 1: To conduct a randomized feasibility trial in adolescent SCD patients with abnormal
nocturnal dipping. Prior to conducting a definitive multicenter trial of losartan to prevent target organ damage
from abnormal nocturnal dipping, a feasibility trial is required to 1) determine the estimated rates of eligibility
and acceptability of enrollment into an adolescent SCD hypertension trial, 2) demonstrate participant
adherence to study medication (daily oral losartan), 3) estimate compliance with study procedures including 24
hour Ambulatory Blood Pressure Monitoring (ABPM) at 0, 3, and 6 months. We anticipate that 30% of cohort
participants (HbSS/SB
0
thalassemia and ages 11-19 years) will have both abnormal nocturnal dipping by
ABPM and hypertension in clinic. We hypothesize that we will need to approach 60 of the 200 cohort
participants to enroll 40 participants in this 6 month feasibility trial of losartan.
Specific Aim 2: To demonstrate in a feasibility trial the optimal dose of losartan and effect size
necessary to conduct a trial of losartan in participants with abnormal nocturnal dipping. To
determine the optimal losartan dose, participants will receive losartan (0.7mg/kg) and randomized to monthly
titration to achieve a clinic BP <95th percentile (standard dosing strategy) or BP <75th percentile (intensive
dosing strategy). A strict data safety plan and monitoring board will evaluate the safety of both dosing
strategies. We hypothesize that intensive losartan dosing is safe to utilize in a clinical trial, will be adhered to
by participants and can be maintained in an open label fashion. To determine the effect size needed to power
a definitive trial of losartan for participants with abnormal nocturnal dipping, ABPM will be performed at
baseline, 3 and 6 months to determine the differences in BP and standard deviation from baseline to exit.
Specific Aim 3: To prospectively evaluate the incidence of hypertension in patients with SCD and the
potential role of biomarkers of disease. Two hundred patients with HbSS or SB0 thalassemia (6-20 yrs) will
enroll in a three year prospective cohort study (At this time: 109 participants consented. Expect 200 enrolled by
2015). Participants will undergo annual 24 hr ABPM and urine/blood biomarkers of kidney injury. Over three
years, we will describe the incidence of hypertension and its association to biomarkers. Additional analysis will
explore the role of SCD therapies (hydroxyurea, transfusion) or laboratory values on these outcomes.
The proposed research will offer insight into the previously unexplored area of antihypertensive therapy in
pediatric SCD. The K23 will provide mentored training in design, conduct, and analysis of clinical trials for a
rare disease, with an emphasis on feasibility and safety monitoring. The results of this proposal will be
incorporated into an R34 application to conduct a multi-center pilot study to demonstrate feasibility of this trial
prior to submission of a R01 application for a definitive trial. This K23 application represents the first step in
developing the expertise and data required to lead the small SCD trialist community in efforts to reduce the
long term, severe complications resulting from untreated hypertension and kidney disease in pediatric SCD.